AR040332A1 - Derivados de acido benzoico como moduladores de ppar alfa y gamma - Google Patents

Derivados de acido benzoico como moduladores de ppar alfa y gamma

Info

Publication number
AR040332A1
AR040332A1 ARP030102199A ARP030102199A AR040332A1 AR 040332 A1 AR040332 A1 AR 040332A1 AR P030102199 A ARP030102199 A AR P030102199A AR P030102199 A ARP030102199 A AR P030102199A AR 040332 A1 AR040332 A1 AR 040332A1
Authority
AR
Argentina
Prior art keywords
aryl
group
alkyl
optionally substituted
fluorine atoms
Prior art date
Application number
ARP030102199A
Other languages
English (en)
Inventor
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR040332A1 publication Critical patent/AR040332A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Así como isómeros ópticos y racematos de los mismos, también sales, profármacos, solvatos y formas cristalinas aceptables para uso farmacéutico de los mismos, procesos para preparar dichos compuestos, su utilidad en el tratamiento de afecciones clínicas asociadas con resistencia a insulina, métodos para su uso terapéutico y composiciones farmacéuticas que contienen las mismas. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) donde: R1 representa arilo sustituido optativamente con un grupo heterocíclico o un grupo heterocíclico sustituido optativamente con un arilo, donde cada arilo o grupo heterocíclico está sustituido optativamente con uno o varios de los siguientes grupos: un grupo alquilo C1-6; un grupo acilo C1-6; aril-alquilo(C1-6), donde el grupo alquilo, arilo o alquilarilo está sustituido optativamente con uno o varios Rb; halógeno, -CN y NO2, -NRcCOORa; -NRcCORa; -NRcRa; -NRcSO2Rd; -NRcCONRkRc; -NRcCSNRaRk; -ORa; -OSO2Rd; -SO2Rd; -SORd; -SRc; -SO2NRaRf; -SO2ORa; -CONRcRa; -OCONRfRa; donde Ra representa H, un grupo alquilo C1-6, un grupo arilo o aril-alquilo(C1-6) donde el grupo alquilo, arilo o aril-alquilo(C1-6) está sustituido optativamente una o más veces con Rb, donde Rb representa alquilo C1-6, arilo, aril-alquilo(C1-6), ciano, -NRcRd, =O, halo, -OH, -SH, -OC-alquilo(C1-4), -O-arilo, -O-alquilarilo C1-4, -CORc, -SRd, -SORd, o -SO2Rd, donde Rc representa H, alquilo C1-4, arilo, aril-alquilo C1-4 y Rd representa C1-4 alquilo, arilo, aril C1-4alquilo; donde Rf representa hidrógeno, alquilo C1-4, acilo C1-4, arilo, aril-alquilo(C1-4) y Ra es como se definió previamente; y Rk representa hidrógeno, alquilo C1-4, arilo, aril-alquilo(C1-4); el grupo -(CH2)mT-(CH2)m-U-(CH2)p- está unido ya sea en posición 3 ó 4 del anillo fenilo según se indica con los números en la fórmula (1) y representa un grupo seleccionado entre uno o varios de los siguientes grupos: -O(CH2)2, -O(CH2)3, NC(O)NR4(CH2)2, CH2S(O2)NR5(CH2), CH2N(R6)C(O)CH2, (CH2)2N(R6)C(O)(CH2)2, C(O)NR7CH2, C(O)NR7(CH2)2 y CH2N(R6)C(O)CH2O; V representa O, S, NR8 o a enlace simple; q representa 1, 2 ó 3; W representa O, S; N(R9)C(O), NR10 o un enlace simple; R2 representa halo, un grupo alquilo C1-4 que está sustituido optativamente con uno o varios átomos de flúor, un grupo alcoxi C1-4 que está sustituido optativamente con uno o varios átomos de flúor, un grupo acilo C1-4, arilo, un grupo aril-alquilo(C1-4), CN o NO2; r representa 0, 1, 2 ó 3; R3 representa halo, un grupo alquilo C1-4 que está sustituido optativamente con uno o varios átomos de flúor, un grupo alcoxi C1-4 que está sustituido optativamente con uno o varios átomos de flúor, un grupo acilo C1-4, arilo, un grupo aril-alquilo(C1-4) o CN; s representa 0, 1, 2, ó 3; y R4, R5, R6, R7, R8, R9 y R10 representan independientemente entre sí H, un grupo alquilo C1-10, arilo o un grupo aril-alquilo(C1-4) o, cuando m es 0 y T representa un grupo N(R6)C(O) o un grupo (R5)NS(O2) entonces R1 y R6 o R1 y R5 forman un grupo heteroarilo junto con el átomo de nitrógeno al cual están unidos; así como isómeros ópticos y racematos de los mismos, así como sales, profármacos, solvatos y formas cristalinas aceptables para uso farmacéutico de los mismos; con la condición que 1) cuando R1 es fenilo sustituido optativamente con uno o dos grupos seleccionados independientemente entre halo, un grupo alquilo C1-4 que está sustituido optativamente con uno o varios átomos de flúor, un grupo alcoxi C1-4 que está sustituido optativamente con uno o varios átomos de flúor; m es 1; T es N(R6)C(O) donde R6 representa un grupo alquilo C2-8 que está interrumpido optativamente con oxígeno; n es 1; U está ausente o representa metileno; p es 0; r es 0; V es O ó S; q es 1; y W es un enlace simple unido en posición orto al grupo ácido carboxílico, entonces s no representa 0; y 2) cuando R1 es fenilo sustituido optativamente con uno o dos grupos seleccionados independientemente entre halo, un grupo alquilo C1.4 que está sustituido optativamente con uno o varios átomos de flúor, un grupo alcoxi C1-4 que está sustituido optativamente con uno o varios átomos de flúor; m es 1; T es N(R6)C(O), donde R6 representa un grupo alquilo C2-7 no ramificado,; n es 1; U es O; p es 0; r es 0 ó 1; y cuando r es 1, R2 está unido en la posición 3 y es OCH3; V es un enlace simple; q es 2; y W es O ó S unido en posición orto al grupo ácido carboxílico; entonces s no representa 0.
ARP030102199A 2002-06-20 2003-06-20 Derivados de acido benzoico como moduladores de ppar alfa y gamma AR040332A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201937A SE0201937D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR040332A1 true AR040332A1 (es) 2005-03-30

Family

ID=20288295

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102199A AR040332A1 (es) 2002-06-20 2003-06-20 Derivados de acido benzoico como moduladores de ppar alfa y gamma

Country Status (21)

Country Link
US (1) US7521461B2 (es)
EP (1) EP1517680A1 (es)
JP (1) JP4327085B2 (es)
KR (1) KR20050014014A (es)
CN (1) CN100400512C (es)
AR (1) AR040332A1 (es)
AU (1) AU2003240101B2 (es)
BR (1) BR0311840A (es)
CA (1) CA2490687A1 (es)
IL (1) IL165672A0 (es)
IS (1) IS7639A (es)
MX (1) MXPA04012694A (es)
NO (1) NO20045222L (es)
NZ (1) NZ536972A (es)
PL (1) PL375078A1 (es)
RU (1) RU2339613C2 (es)
SE (1) SE0201937D0 (es)
TW (1) TW200403209A (es)
UA (1) UA77527C2 (es)
WO (1) WO2004000295A1 (es)
ZA (1) ZA200409690B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
DK1517883T3 (da) * 2002-06-20 2008-05-26 Astrazeneca Ab Ortho-substituerede benzoesyrederivater til behandling af insulinresistens
US7351858B2 (en) 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
JP4531049B2 (ja) * 2003-09-17 2010-08-25 ノバルティス アーゲー 有機化合物
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
KR101328273B1 (ko) * 2004-12-28 2013-11-14 키넥스 파마슈티컬즈, 엘엘씨 세포 증식 질환의 치료를 위한 조성물 및 방법
US7816405B2 (en) * 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
WO2007030567A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
JP2007234800A (ja) 2006-02-28 2007-09-13 Tdk Corp 電子部品及びその製造方法
PL2514742T3 (pl) * 2006-03-31 2015-07-31 Univ Texas Leki przeciwnowotworowe będące pochodnymi kwasu kawowego dostępnymi biologicznie po podaniu doustnym
AU2007265373B2 (en) * 2006-06-29 2013-02-21 Atnx Spv, Llc Biaryl compositions and methods for modulating a kinase cascade
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
BRPI0810525B8 (pt) 2007-04-11 2021-05-25 Omeros Corp uso de pioglitazona ou rosiglitazona pra tratar a dependência em álcool, cocaína e nicotina, composições farmacêuticas e formas de dosagem, e combinações farmacêuticas contendo pioglitazona ou rosiglitazona
CA2796419C (en) 2010-04-16 2018-11-06 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
WO2013019621A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
TWI664167B (zh) 2012-08-30 2019-07-01 美商艾瑟奈克斯公司 用於調節激酶級聯之組成物及方法
EP3719010B1 (en) * 2017-11-30 2023-07-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Aromatic compound, pharmaceutical composition thereof and use thereof
US20230077316A1 (en) * 2020-10-23 2023-03-09 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
US5334753A (en) 1992-03-12 1994-08-02 Rhone-Poulenc Agriculture Ltd Processes for preparing ortho-substituted benzoic acids
DE19615263A1 (de) 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
DE19616948C1 (de) 1996-04-27 1997-11-27 Wagner Gmbh J Schneidwerkzeug, insbesondere Astschere
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
EP1030665A4 (en) 1997-10-17 2002-11-27 Aventis Pharm Prod Inc THERAPEUTIC USE OF CHINOLINE DERIVATIVES
CA2315070A1 (en) 1997-12-17 1999-07-01 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
ES2287016T3 (es) 1999-04-28 2007-12-16 Sanofi-Aventis Deutschland Gmbh Derivados de diaril-acido como ligandos del receptor ppar.
JP2002543065A (ja) 1999-04-28 2002-12-17 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｐ受容体リガンドとしてのトリアリール酸誘導体
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6509374B2 (en) 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
ZA200409690B (en) 2005-10-11
IL165672A0 (en) 2006-01-15
EP1517680A1 (en) 2005-03-30
BR0311840A (pt) 2005-03-15
US7521461B2 (en) 2009-04-21
WO2004000295A1 (en) 2003-12-31
KR20050014014A (ko) 2005-02-05
NZ536972A (en) 2006-06-30
TW200403209A (en) 2004-03-01
CN100400512C (zh) 2008-07-09
AU2003240101B2 (en) 2006-09-21
UA77527C2 (en) 2006-12-15
US20050267149A1 (en) 2005-12-01
AU2003240101A1 (en) 2004-01-06
NO20045222L (no) 2005-01-19
PL375078A1 (en) 2005-11-14
JP4327085B2 (ja) 2009-09-09
RU2339613C2 (ru) 2008-11-27
SE0201937D0 (sv) 2002-06-20
IS7639A (is) 2005-01-12
JP2006502105A (ja) 2006-01-19
MXPA04012694A (es) 2005-03-23
CN1662230A (zh) 2005-08-31
CA2490687A1 (en) 2003-12-31
RU2004135542A (ru) 2005-08-10

Similar Documents

Publication Publication Date Title
AR040332A1 (es) Derivados de acido benzoico como moduladores de ppar alfa y gamma
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
ES2655391T3 (es) Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
AR050698A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto
AR060268A1 (es) Tiazolil - dihidro - indazoles
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
AR041260A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
AR037288A1 (es) Compuestos derivados de sulfonamidas, procedimiento para la obtencion, composicion farmaceutica y uso para la elaboracion de un medicamento
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR038834A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco
AR045260A1 (es) Compuestos que contienen imidazo-oxima sustituidos
AR046781A1 (es) Derivados de imidazoquinolinas. composiciones farmaceuticas.
AR059687A1 (es) Derivados de pirazol inhibidores de la enzima mao-b,utiles para mejorar la funcion cognitiva, composiciones farmaceuticas que los contienen,y metodo de preparacion.
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
AR045955A1 (es) Compuestos benzoimidazolicos
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
HUP0300920A1 (hu) Szubsztituált benzidszármazékok és gyógyszerként történő felhasználásuk
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
JP2016513076A5 (es)
AR060265A1 (es) Tiazolil - dihidro -quinazolinas
AR055744A1 (es) Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos
AR060267A1 (es) Tiazolil- dihidro -ciclopentapirazoles
AR079783A1 (es) Derivados de tienopirrol, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las proteinas quinasas
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye

Legal Events

Date Code Title Description
FA Abandonment or withdrawal